Xu Jie, Deng Wei, Zhu Xun, Han Deyu, Zheng Yu, Zheng Qun
Department of Rheumatology Immunology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Internal Medicine, Mianning County People's Hospital, Wenzhou, China.
Front Pharmacol. 2025 Feb 19;16:1508971. doi: 10.3389/fphar.2025.1508971. eCollection 2025.
Icariin (ICA), one of the main active components of , is reported to revere osteonecrosis of the femoral head (ONFH). The aim of this study is to further explore the mechanisms and efficacy of ICA in animal models of ONFH and simultaneously analyze methodological issues in the field of researches.
According to the established search strategy, we searched 14 studies from eight databases from their inception dates to November 2024. The CAMARADES 10-item checklist was utilized to evaluate the methodological quality of the stuies and Rev-Man 5.3 software to analyze differences in outcome indicators.
The quality score for the included articles ranges from 1/10 to 6/10 with an average of 4.5 and the defects in aspects of blinding assessment of outcome, randomization and sample size calculation are the main losing points. Compared with the control group, 10 stuies reported ICA could partially improve bone pathology including reducing the empty of bone lacunae, maturing osteoblasts of ONFH and decreasing chondroid bone matrix and fibrous connective tissue. Eight stuies indicates that ICA could improve bone-related parameters under imageology including F-BMD, Tb.N, Tb.Th, BV/TV and Tb. Sp.
The preclinical systematic review provided preliminary evidence that ICA partially reversing ONFH in animal models probably via promoting angiogenesis, anti-apoptosis, and regulating the activities of osteoblasts and osteoclasts. Randomization, blinding and sample size calculation should be focused on in future studies of ONFH. These findings suggest that ICA is a potential candidate for further clinical trials of ONFH.
淫羊藿苷(ICA)是淫羊藿的主要活性成分之一,据报道可改善股骨头坏死(ONFH)。本研究旨在进一步探讨ICA在ONFH动物模型中的作用机制和疗效,并同时分析该研究领域中的方法学问题。
根据既定的检索策略,我们检索了8个数据库从建库至2024年11月的14项研究。采用CAMARADES 10项清单评估研究的方法学质量,并使用Rev-Man 5.3软件分析结局指标的差异。
纳入文章的质量得分在1/10至6/10之间,平均为4.5分,结局的盲法评估、随机化和样本量计算方面的缺陷是主要失分点。与对照组相比,10项研究报告ICA可部分改善骨病理学,包括减少骨陷窝空虚、促进ONFH的成骨细胞成熟以及减少软骨样骨基质和纤维结缔组织。8项研究表明ICA可改善影像学下的骨相关参数,包括股骨骨密度(F-BMD)、骨小梁数量(Tb.N)、骨小梁厚度(Tb.Th)、骨体积分数(BV/TV)和骨小梁间距(Tb.Sp)。
临床前系统评价提供了初步证据,表明ICA可能通过促进血管生成、抗凋亡以及调节成骨细胞和破骨细胞的活性来部分逆转动物模型中的ONFH。在未来的ONFH研究中应关注随机化、盲法和样本量计算。这些发现表明ICA是ONFH进一步临床试验的潜在候选药物。